Statement by Mr. Nicolas Sarkozy, President of the Republic, on the fight against Alzheimer's disease, in Paris on July 20, 2011.

France Nicolas Sarkozy · President of France

20 July 2011 · International Conference on Alzheimer's Disease · Paris, France

Context
Sarkozy addressed the International Conference on Alzheimer's Disease in Paris on July 20, 2011, outlining France's national plan and global commitments to combat the disease.
Main themes
Alzheimer's disease, international research cooperation, France's national Alzheimer's plan, patient care and support, family solidarity, aging populations, public health funding, social and ethical responsibility, global prevalence of dementia, medical research progress
Duration
~15 min
53rd percentile
Words
1,836
53rd percentile
Sentences
89
57th percentile
Readability
39
35th percentile
Grade
12.8
54th percentile
Syntax
2.97
44th percentile
Vocabulary
2.27
67th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 63%63%
  • Ceremonial 12%12%
  • Economic 9%9%
  • Institutional 9%9%
  • Geopolitical 4%4%
  • Technological 2%2%
  • Environmental 0%0%
  • Not in focus 0%

89 sentences in 41 paragraphs

Ladies and Gentlemen Ministers,

Ladies and Gentlemen,

I am very pleased that France is hosting the International Conference on Alzheimer's Disease for the first time. As you know, I have made the fight against Alzheimer's disease a priority of my action since 2007. The presence in France of the world's leading specialists in this disease is an honor for our country, a recognition for our researchers, and an encouragement for the French Government to continue its commitment in this area.

Your work and discussions illustrate the immense research effort that the international community has launched to conquer Alzheimer's disease. You embody the excellence of global science, you embody hope for the millions of patients who suffer and for their loved ones who accompany them through this ordeal.

Alzheimer's disease is a terrible affliction that attacks the very identity of the individual: their memory and their relationship with time, their ability to think, their ability to interact with family and friends, and even their ability to navigate in space. The suffering of the patient is also that of their surroundings, who must gradually take over everything the patient can no longer do alone.

What solidarity can we put in place to support Alzheimer's patients? What support do we provide to families? What place do families and society give to their elders? All these questions go beyond the issue of care or treatment. We must keep all these questions in mind when we address Alzheimer's disease or old age, whether we are political leaders, doctors, or researchers.

These questions resonate daily for our fellow citizens, those who suffer from the disease, those who accompany a loved one and are present by their side, those who provide care and assistance to them.

Behind the research on Alzheimer's disease, behind the care infrastructures, behind the funding, it is the humanity of our society that is at stake, through the place it gives to the most vulnerable, and its ability to protect those who can no longer take care of themselves.

The face of a parent, a loved one affected by this disease, is that of millions of patients around the world. It embodies a disease that is one of the main challenges for medicine in the 21st century.

For with the increase in life expectancy worldwide and the aging of populations, the disease is inexorably developing. Certainly, elderly people are not the only ones affected, but the risk of developing the disease doubles every 5 years after the age of 65, and among those over 85, one in five is affected.

However, we must challenge preconceived ideas: this disease does not only concern wealthy and aging countries.

Today, more than 35 million people worldwide are affected by Alzheimer's disease. Two-thirds live in poor or developing countries. By 2030, the world will have 65 million patients, equivalent to the population of France. 1% of global wealth is already dedicated to the care and management of Alzheimer's disease and related diseases.

The fight against Alzheimer's disease is a health and ethical priority. It is also a major social and economic challenge for all countries in the world.

In France, 850,000 people are already affected by Alzheimer's disease and related diseases. As early as 2007, I wanted us to establish a comprehensive diagnosis of the needs for patient care and support for their families.

Following this study, we launched the Alzheimer's plan for the period 2008-2012, which covers the three aspects of the disease: care, support, and research. We want to equip France with a comprehensive system, throughout its territory, so that no Alzheimer's patient is overlooked, so that no family is left without assistance, and so that no research avenue is neglected.

For each of these three areas, we have established clear objectives, identified funding, and designated leaders.

Twice a year, I personally bring together all the stakeholders of the plan to monitor its progress. Every French citizen, and each of you, can follow the progress of the plan by consulting the feedback available online.

We have allocated a considerable budget: 1.6 billion euros, of which 200 million is dedicated to research.

I spoke of concrete objectives: for patients, we have strengthened the network of consultations accessible throughout the territory. We have also created the MAIA, Houses for the Autonomy and Integration of Alzheimer's patients, which help guide patients and offer them the most suitable solution for their situation. Each region already has one or more MAIA, and there will be more than a hundred by the end of 2012.

At the same time, we have developed care and support infrastructures, considering all solutions, so that each patient can, as far as possible, choose between hospitalization, institutional care, and home care. To meet these various expectations, we have launched a massive training effort for medical and paramedical staff. Today, our country already counts 145 activity and care poles in establishments, 42 hospital units specialized in behavioral disorders, and 111 teams specialized in home care.

We have established a national steering mission, led by Ms. Florence LUSTMAN, whose determination and rigor I want to commend. And we have also created the Alzheimer Plan Foundation, a light and responsive structure to coordinate scientific cooperation and bring together all stakeholders. I want to commend Joël MENARD, Philippe LAGAYETTE, and Philippe AMOUYEL, who, at its head, are doing absolutely remarkable work.

The Foundation notably facilitates interactions between public and private research, which are so necessary to explore new avenues and develop new treatments.

This Alzheimer plan is indeed an unprecedented support for research. Since 2008, more than 600 doctors have been trained in clinical research on Alzheimer's disease. In research laboratories, about a hundred students have received a scholarship to dedicate their thesis to it, and nearly 40 post-doctoral researchers have received funding for their research. In hospitals, 50 positions for clinical chiefs and hospital-university assistants will be created by 2012, and installation grants have been established to attract even more skills and teams to France.

We have chosen to mobilize researchers in all fields, in fundamental research, in clinical research, in the field of social sciences, because we must progress both in understanding the disease, in its management, in its detection, and also in improving the quality of life of patients.

Today, the Alzheimer plan finances more than 100 research projects. Of the 200 million euros planned for 5 years, 70 have already been allocated.

Thanks to its rapid and effective action, the Alzheimer Plan has accelerated research, and the first studies have already been published. Our knowledge has progressed remarkably: new predisposition factors for Alzheimer's disease have thus been highlighted. Certainly, we still do not fully understand the causes of the appearance and accumulation of the plaques responsible for the disease, but the proteins involved in these mechanisms are the subject of numerous research projects, which we hope will soon bear fruit.

I know that a session of your congress has been dedicated to genomic studies using high-tech tools. In this area too, the French Plan has played a key role: France has led a European program that has allowed the comparison of the DNA of thousands of patients with that of control subjects. This has enabled the identification of new genetic mutations that predispose to the onset of the disease. Beyond measuring risk, this discovery opens new research avenues and, potentially, new therapeutic pathways.

We have also strengthened the infrastructures available to researchers. 27 Memory Resource and Research Centers offer high-level clinical research.

They will notably allow the gathering of the 2,500 patients from the "Memento" cohort, which will provide researchers with the necessary information to study the natural history of the disease at a very early stage.

All these advances born from the Alzheimer Plan add to the immense effort that our country has deployed in favor of higher education and research since 2007. We have given our universities the autonomy and means to develop in an international environment. They can now establish partnerships, attract the best researchers and the best teachers. Since 2007, the State's investment in higher education and research has increased by one billion euros each year.

These reforms are supported by the funding from the Future Investments, which allow our country to prepare for the post-crisis period by encouraging employment, competitiveness, and the research of tomorrow. As part of this investment program, 20 billion euros are thus allocated to higher education and research, of which 2.5 billion will be dedicated to the field of Health and Biotechnology. I insisted that projects be selected based on criteria of excellence and by juries comprising the best specialists in the world.

Many projects selected by the jury concern neuroscience and neurological disorders. I think of the Hospital-University Institute of Neurosciences in Paris, which brings together INSERM, the Pitié-Salpêtrière Hospital, and Pierre and Marie Curie University. It will be endowed with 55 million euros. Several laboratories focusing on neurology have also received the "Laboratory of Excellence" label, notably the NUMEV project in Montpellier and BRAIN in Bordeaux.

As you can see, Ladies and Gentlemen, research on Alzheimer's disease finds in France a particularly favorable environment, as our country has equipped itself with the tools allowing investors to find an attractive fiscal environment and researchers to give their best.

You who represent the greatest research teams in the world here, you know well that nothing great is done in solitude - this is true for science as for any human endeavor. The international dimension is crucial to serve science and medicine in the age of cutting-edge technologies and global health challenges.

I am pleased that the international program on the genomics of Alzheimer's disease, the IGAP program, has gathered on the occasion of the ICAD in Paris.

This unique collaboration brings together the four largest European and North American consortiums to study the genetic predispositions to Alzheimer's disease that I mentioned earlier. If over the past two years more than 10 new genes have been identified, it is because these international collaborations have multiplied. Your working sessions during this congress have further testified to this.

This openness to international collaborations, France defended it during its Presidency of the European Union in 2008. Now, 23 European countries are uniting their forces in common research programs, particularly in the fight against Alzheimer's disease, by reserving funds in their budgets for this purpose.

We must bring together scientific intelligence and talent and provide them with the most effective tools. Because the cause that unites us today, alleviating the suffering of patients and their families, is too important for national particularisms, ego conflicts, and administrative delays to persist.

Seeing your dynamism and creativity, I know that international research has entered a new phase.

I want to assure you that the determination of public authorities and political leaders is total. Like you, they want to abandon the old patterns of national retreat and partisan interests, to prioritize the protection of each individual and the interest of all. You can count on France to contribute to this.

Thank you.